-DOCSTART- -X- O
Herpes -X- _ B-Intervention
simplex -X- _ I-Intervention
virus -X- _ I-Intervention
type -X- _ I-Intervention
1 -X- _ I-Intervention
( -X- _ I-Intervention
HSV1 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
when -X- _ O
present -X- _ O
in -X- _ O
brain -X- _ O
of -X- _ O
carriers -X- _ O
of -X- _ O
the -X- _ O
type -X- _ O
4 -X- _ O
allele -X- _ O
of -X- _ O
the -X- _ O
apolipoprotein -X- _ O
E -X- _ O
gene -X- _ O
( -X- _ O
APOE -X- _ O
) -X- _ O
, -X- _ O
has -X- _ O
been -X- _ O
implicated -X- _ O
as -X- _ O
a -X- _ O
major -X- _ O
factor -X- _ O
in -X- _ O
Alzheimer’s -X- _ B-Patient
disease -X- _ I-Patient
( -X- _ I-Patient
AD -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
It -X- _ O
is -X- _ O
proposed -X- _ O
that -X- _ O
virus -X- _ O
is -X- _ O
normally -X- _ O
latent -X- _ O
in -X- _ O
many -X- _ O
elderly -X- _ O
brains -X- _ O
but -X- _ O
reactivates -X- _ O
periodically -X- _ O
( -X- _ O
as -X- _ O
in -X- _ O
the -X- _ O
peripheral -X- _ O
nervous -X- _ O
system -X- _ O
) -X- _ O
under -X- _ O
certain -X- _ O
conditions -X- _ O
, -X- _ O
for -X- _ O
example -X- _ O
stress -X- _ O
, -X- _ O
immunosuppression -X- _ O
, -X- _ O
and -X- _ O
peripheral -X- _ O
infection -X- _ O
, -X- _ O
causing -X- _ O
cumulative -X- _ O
damage -X- _ O
and -X- _ O
eventually -X- _ O
development -X- _ O
of -X- _ O
AD. -X- _ O
Diverse -X- _ O
approaches -X- _ O
have -X- _ O
provided -X- _ O
data -X- _ O
that -X- _ O
explicitly -X- _ O
support -X- _ O
, -X- _ O
directly -X- _ O
or -X- _ O
indirectly -X- _ O
, -X- _ O
these -X- _ O
concepts. -X- _ O
Several -X- _ O
have -X- _ O
confirmed -X- _ O
HSV1 -X- _ B-Outcome
DNA -X- _ I-Outcome
presence -X- _ I-Outcome
in -X- _ I-Outcome
human -X- _ I-Outcome
brains -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
HSV1-APOE-ε4 -X- _ I-Outcome
association -X- _ I-Outcome
in -X- _ I-Outcome
AD. -X- _ I-Outcome
Further -X- _ O
, -X- _ O
studies -X- _ O
on -X- _ O
HSV1-infected -X- _ B-Outcome
APOE-transgenic -X- _ I-Outcome
mice -X- _ I-Outcome
have -X- _ I-Outcome
shown -X- _ I-Outcome
that -X- _ I-Outcome
APOE-e4 -X- _ I-Outcome
animals -X- _ I-Outcome
display -X- _ I-Outcome
a -X- _ I-Outcome
greater -X- _ I-Outcome
potential -X- _ I-Outcome
for -X- _ I-Outcome
viral -X- _ I-Outcome
damage. -X- _ I-Outcome
Reactivated -X- _ I-Outcome
HSV1 -X- _ I-Outcome
can -X- _ I-Outcome
cause -X- _ I-Outcome
direct -X- _ I-Outcome
and -X- _ I-Outcome
inflammatory -X- _ I-Outcome
damage -X- _ I-Outcome
, -X- _ I-Outcome
probably -X- _ I-Outcome
involving -X- _ I-Outcome
increased -X- _ I-Outcome
formation -X- _ I-Outcome
of -X- _ I-Outcome
beta -X- _ I-Outcome
amyloid -X- _ I-Outcome
( -X- _ I-Outcome
Aβ -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
of -X- _ I-Outcome
AD-like -X- _ I-Outcome
tau -X- _ I-Outcome
( -X- _ I-Outcome
P-tau -X- _ I-Outcome
) -X- _ I-Outcome
—changes -X- _ I-Outcome
found -X- _ I-Outcome
to -X- _ I-Outcome
occur -X- _ I-Outcome
in -X- _ I-Outcome
HSV1-infected -X- _ I-Outcome
cell -X- _ I-Outcome
cultures. -X- _ I-Outcome
Implicating -X- _ I-Outcome
HSV1 -X- _ I-Outcome
further -X- _ I-Outcome
in -X- _ I-Outcome
AD -X- _ I-Outcome
is -X- _ I-Outcome
the -X- _ I-Outcome
discovery -X- _ I-Outcome
that -X- _ I-Outcome
HSV1 -X- _ I-Outcome
DNA -X- _ I-Outcome
is -X- _ I-Outcome
specifically -X- _ I-Outcome
localized -X- _ I-Outcome
in -X- _ I-Outcome
amyloid -X- _ I-Outcome
plaques -X- _ I-Outcome
in -X- _ I-Outcome
AD. -X- _ I-Outcome
Other -X- _ O
relevant -X- _ O
, -X- _ O
harmful -X- _ O
effects -X- _ O
of -X- _ O
infection -X- _ O
include -X- _ O
the -X- _ O
following -X- _ O
: -X- _ O
dynamic -X- _ B-Outcome
interactions -X- _ I-Outcome
between -X- _ I-Outcome
HSV1 -X- _ I-Outcome
and -X- _ I-Outcome
amyloid -X- _ I-Outcome
precursor -X- _ I-Outcome
protein -X- _ I-Outcome
( -X- _ I-Outcome
APP -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
would -X- _ I-Outcome
affect -X- _ I-Outcome
both -X- _ I-Outcome
viral -X- _ I-Outcome
and -X- _ I-Outcome
APP -X- _ I-Outcome
transport -X- _ I-Outcome
; -X- _ I-Outcome
induction -X- _ I-Outcome
of -X- _ I-Outcome
toll-like -X- _ I-Outcome
receptors -X- _ I-Outcome
( -X- _ I-Outcome
TLRs -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
HSV1-infected -X- _ I-Outcome
astrocyte -X- _ I-Outcome
cultures -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
has -X- _ I-Outcome
been -X- _ I-Outcome
linked -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
likely -X- _ I-Outcome
effects -X- _ I-Outcome
of -X- _ I-Outcome
reactivation -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
virus -X- _ I-Outcome
in -X- _ I-Outcome
brain. -X- _ I-Outcome
Several -X- _ O
epidemiological -X- _ O
studies -X- _ O
have -X- _ O
shown -X- _ O
, -X- _ O
using -X- _ O
serological -X- _ O
data -X- _ O
, -X- _ O
an -X- _ B-Outcome
association -X- _ I-Outcome
between -X- _ I-Outcome
systemic -X- _ I-Outcome
infections -X- _ I-Outcome
and -X- _ I-Outcome
cognitive -X- _ I-Outcome
decline -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
HSV1 -X- _ I-Outcome
particularly -X- _ I-Outcome
implicated. -X- _ I-Outcome
Genetic -X- _ O
studies -X- _ O
too -X- _ O
have -X- _ O
linked -X- _ B-Outcome
various -X- _ I-Outcome
pathways -X- _ I-Outcome
in -X- _ I-Outcome
AD -X- _ I-Outcome
with -X- _ I-Outcome
those -X- _ I-Outcome
occurring -X- _ I-Outcome
on -X- _ I-Outcome
HSV1 -X- _ I-Outcome
infection. -X- _ I-Outcome
In -X- _ O
relation -X- _ O
to -X- _ O
the -X- _ O
potential -X- _ O
usage -X- _ O
of -X- _ O
antivirals -X- _ O
to -X- _ O
treat -X- _ O
AD -X- _ O
patients -X- _ O
, -X- _ O
acyclovir -X- _ O
( -X- _ O
ACV -X- _ O
) -X- _ O
is -X- _ O
effective -X- _ O
in -X- _ O
reducing -X- _ O
HSV1-induced -X- _ O
AD-like -X- _ O
changes -X- _ O
in -X- _ O
cell -X- _ O
cultures -X- _ O
, -X- _ O
and -X- _ O
valacyclovir -X- _ O
, -X- _ O
the -X- _ O
bioactive -X- _ O
form -X- _ O
of -X- _ O
ACV -X- _ O
, -X- _ O
might -X- _ O
be -X- _ O
most -X- _ O
effective -X- _ O
if -X- _ O
combined -X- _ O
with -X- _ O
an -X- _ O
antiviral -X- _ O
that -X- _ O
acts -X- _ O
by -X- _ O
a -X- _ O
different -X- _ O
mechanism -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
intravenous -X- _ O
immunoglobulin -X- _ O
( -X- _ O
IVIG -X- _ O
) -X- _ O
. -X- _ O

